AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10365734 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol combined with micronized progesterone
Number of subjects: 37
Study 10365734 — intervention group
Group type: COMPARATOR
Intervention: No hormonal treatment
Number of subjects: 37
Study 7497717 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia/epidural opiate analgesia (regional anesthesia)
Number of subjects: 60
Study 7497717 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia/intravenous patient‐controlled analgesia (general anesthesia)
Number of subjects: 60
Study 7497717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 2042443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg, b.i.d., for 60 days
Number of subjects: 37
Study 2042443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 6794585 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm, humidified air
Number of subjects: 85
Study 6794585 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 31468528 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Acceptance and Commitment Therapy (ACT) program
Number of subjects: 1162
Study 31468528 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 1162
Study 30167045 — intervention group
Group type: EXPERIMENTAL
Intervention: 80mg/8ml intravenous phloroglucinol
Number of subjects: 122
Study 30167045 — intervention group
Group type: COMPARATOR
Intervention: 8ml of sterile water (placebo)
Number of subjects: 122
Study 27393928 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive systemic amoxicillin 500 mg plus metronidazole 400 mg (3×/day, 7 days)
Number of subjects: 345
Study 27393928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study 27393928 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive systemic amoxicillin plus metronidazole
Number of subjects: 345
Study 24346594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled beclomethasone (n = 86)
Number of subjects: 185
Study 24346594 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 99)
Number of subjects: 185
Study 22435244 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) based ART
Number of subjects: 121
Study 22435244 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) based ART
Number of subjects: 121
Study 22435244 — intervention group
Group type: COMPARATOR
Intervention: Both NVP and EFV groups
Number of subjects: 121
Study 22435244 — intervention group
Group type: COMPARATOR
Intervention: EFV group
Number of subjects: 121
Study 19878037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide-liberating cream applied twice daily for 10 days
Number of subjects: 64
Study 19878037 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 10 days
Number of subjects: 64
Study 19189566 — intervention group
Group type: EXPERIMENTAL
Intervention: Antismoking counseling
Number of subjects: 199
Study 19189566 — intervention group
Group type: COMPARATOR
Intervention: Control activities
Number of subjects: 199
Study 15668495 — intervention group
Group type: EXPERIMENTAL
Intervention: False-positive prostate cancer screening results
Number of subjects: 2290
Study 15668495 — intervention group
Group type: COMPARATOR
Intervention: Negative prostate cancer screening results
Number of subjects: 2290
Study 12912723 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (2 micro g/kg per minute, adjusted to maintain aPTT at 1.5 to 3 times baseline for 5 to 7 days)
Number of subjects: 418
Study 12912723 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 418
Study 12912723 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 418
Study 10594402 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 0
Study 10594402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8607727 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure physical activity (moderate and heavy)
Number of subjects: 851
Study 8607727 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure physical activity (heavy)
Number of subjects: 851
Study 8607727 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure physical activity (highest intensity)
Number of subjects: 851
Study 8607727 — intervention group
Group type: EXPERIMENTAL
Intervention: Home physical activity (heavy)
Number of subjects: 851
Study 8607727 — intervention group
Group type: COMPARATOR
Intervention: Leisure, occupational, or home physical activity
Number of subjects: 851
Study 1673210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive fly control measures (bait and trap strategy)
Number of subjects: 0
Study 1673210 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fly control measures)
Number of subjects: 0
Study 7277107 — intervention group
Group type: COMPARATOR
Intervention: Pooled breast milk (PBM)
Number of subjects: 24
Study 7277107 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's own milk (PT)
Number of subjects: 24
Study 7277107 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula (SMA24)
Number of subjects: 24
Study 7277107 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula (SMA20)
Number of subjects: 24
Study 30559023 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-unexposed children
Number of subjects: 453
Study 30559023 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-exposed children
Number of subjects: 453
Study 30559023 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-exposed infants
Number of subjects: 453
Study 30546024 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants aged 40-79 years
Number of subjects: 12013
Study 30546024 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age, male sex, and widowed marital status
Number of subjects: 12013
Study 30546024 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents aged 80 years and over
Number of subjects: 12013
Study 30546024 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher blood level of total cholesterol
Number of subjects: 12013
Study 30546024 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants with lower level of high density lipoprotein cholesterol and higher level of uric acid
Number of subjects: 12013
Study 30546024 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal illness such as hypertension, diabetes mellitus, dyslipidemia, myocardial infarction, heart failure, stroke, and transient ischemic attack
Number of subjects: 12013
Study 26506138 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 2% topical solution BID
Number of subjects: 260
Study 26506138 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control solution
Number of subjects: 260
Study 24857600 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal setting intervention
Number of subjects: 724
Study 22240928 — intervention group
Group type: EXPERIMENTAL
Intervention: BWD+PHMB
Number of subjects: 38
Study 22240928 — intervention group
Group type: COMPARATOR
Intervention: Ag
Number of subjects: 38
Study 19937367 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF expression in vestibular schwannomas
Number of subjects: 0
Study 19937367 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BDNF with Ki-67 labelling index
Number of subjects: 0
Study 19937367 — intervention group
Group type: COMPARATOR
Intervention: Expression of other neurotrophic factors (artemin, GDNF)
Number of subjects: 0
Study 18616586 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in resistant starch (RS)
Number of subjects: 46
Study 18616586 — intervention group
Group type: COMPARATOR
Intervention: Diet high in nonstarch polysaccharides (NSP)
Number of subjects: 46
Study 15807754 — intervention group
Group type: EXPERIMENTAL
Intervention: Written education
Number of subjects: 245
Study 15807754 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal education (in addition to written education)
Number of subjects: 245
Study 12270990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapure dialysate
Number of subjects: 30
Study 12270990 — intervention group
Group type: COMPARATOR
Intervention: Conventional dialysate
Number of subjects: 30
Study 9814743 — intervention group
Group type: COMPARATOR
Intervention: Routine consent only
Number of subjects: 32
Study 9814743 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine consent with added verbal information
Number of subjects: 32
Study 9814743 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine consent with added written information
Number of subjects: 32
Study 9814743 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine consent with added written and verbal information
Number of subjects: 32
Study 9814743 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 32
Study 7645037 — intervention group
Group type: EXPERIMENTAL
Intervention: BT563 (murine IgG1 anti-IL-2R antibody)
Number of subjects: 56
Study 7645037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 7645037 — intervention group
Group type: EXPERIMENTAL
Intervention: BT563
Number of subjects: 56
Study 2650603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal symptoms and hiatal hernia
Number of subjects: 50
Study 2650603 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartburn at night
Number of subjects: 50
Study 2650603 — intervention group
Group type: EXPERIMENTAL
Intervention: Regurgitation
Number of subjects: 50
Study 2650603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough
Number of subjects: 50
Study 792789 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) (6 to 14 cm H2O)
Number of subjects: 72
Study 792789 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 72
Study 792789 — intervention group
Group type: COMPARATOR
Intervention: Control (oxygen and mechanical ventilation if needed)
Number of subjects: 72
Study 792789 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP
Number of subjects: 72
Study 31664429 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 251
Study 31664429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 29137160 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with Australian Melaleuca alternifolia oil (TTO) and ethanolic extract of Polish propolis (EEP)
Number of subjects: 51
Study 29137160 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste without TTO and EEP
Number of subjects: 51
Study 25828172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive existential couple therapy (CECT)
Number of subjects: 62
Study 23328270 — intervention group
Group type: EXPERIMENTAL
Intervention: EZG 200 mg + ethanol 1 g/kg
Number of subjects: 17
Study 23328270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 1 g/kg
Number of subjects: 17
Study 23328270 — intervention group
Group type: EXPERIMENTAL
Intervention: EZG 200 mg
Number of subjects: 17
Study 23328270 — intervention group
Group type: COMPARATOR
Intervention: Placebo + ethanol placebo
Number of subjects: 17
Study 19520745 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning training
Number of subjects: 34
Study 19520745 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 34
Study 19447249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential docetaxel after anthracycline chemotherapy (FEC for four cycles followed by docetaxel 100 mg/m2 for four cycles)
Number of subjects: 4162
Study 19447249 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (FEC for eight cycles or epirubicin for four cycles followed by CMF for four cycles)
Number of subjects: 4162
Study 19447249 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (sequential docetaxel)
Number of subjects: 4162
Study 19447249 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4162
Study 17007812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 225
Study 17007812 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group intervention
Number of subjects: 225
Study 17007812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Number of subjects: 225
Study 17007812 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 225
Study 17007812 — intervention group
Group type: EXPERIMENTAL
Intervention: Journaling
Number of subjects: 225
Study 17007812 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 225
Study 14977675 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 180
Study 14977675 — intervention group
Group type: COMPARATOR
Intervention: Brace-only treatment
Number of subjects: 180
Study 14977675 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 180
Study 11345223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (600 mg twice daily)
Number of subjects: 111
Study 11345223 — intervention group
Group type: COMPARATOR
Intervention: Indinavir (800 mg 3 times daily)
Number of subjects: 111
Study 11345223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir/saquinavir (400 mg each twice daily)
Number of subjects: 111
Study 11345223 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PI treatment
Number of subjects: 111
Study 9696508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study 9696508 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 0
Study 9696508 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytically oriented therapy
Number of subjects: 0
Study 9696508 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy
Number of subjects: 0
Study 9696508 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy combined with imipramine
Number of subjects: 0
Study 9696508 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with imipramine
Number of subjects: 0
Study 9696508 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 0
Study 8029809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS)
Number of subjects: 10
Study 8029809 — intervention group
Group type: COMPARATOR
Intervention: Heparin (H)
Number of subjects: 10
Study 2809693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg b.i.d. for 10 to 11 days
Number of subjects: 30
Study 2809693 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 500 mg t.i.d. for 10 to 11 days
Number of subjects: 30
Study 4573315 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenformin and ethyloestrenol
Number of subjects: 13
Study 4573315 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenformin and stanozolol
Number of subjects: 13
Study 4573315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30849250 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil patient‐controlled intravenous labor analgesia (Group A)
Number of subjects: 120
Study 30849250 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient‐controlled epidural analgesia (PCEA) (Group B)
Number of subjects: 120
Study 30849250 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous labor (Group C)
Number of subjects: 120
Study 31336570 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk containing 40 billion of Lactobacillus casei Shirota (LcS) per day (LcS group, n = 20)
Number of subjects: 42
Study 31336570 — intervention group
Group type: COMPARATOR
Intervention: Placebo (unfermented milk, n = 22)
Number of subjects: 42
Study 27966237 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab (15 mg/kg), Epirubicin (50 mg/m2), Cisplatin (60 mg/m2), Capecitabine (625 mg/m2 twice daily)
Number of subjects: 609
Study 27966237 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Number of subjects: 609
Study 25139606 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor feedback
Number of subjects: 99
Study 25139606 — intervention group
Group type: COMPARATOR
Intervention: Control (no instructor feedback)
Number of subjects: 99
Study 25139606 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at follow-up
Number of subjects: 99
Study 24225201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (2.5 to 7.5mg bid)
Number of subjects: 6505
Study 24225201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6505
Study 24225201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6505
Study 22168585 — intervention group
Group type: EXPERIMENTAL
Intervention: Team midwifery
Number of subjects: 0
Study 22168585 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseload midwifery
Number of subjects: 0
Study 22168585 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 17828747 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glucocorticoids (prednisone or dexamethasone)
Number of subjects: 64
Study 17828747 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ACTH (LD-ACTH) stimulation
Number of subjects: 64
Study 17828747 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up LD-ACTH testing
Number of subjects: 64
Study 16796788 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab as a single agent
Number of subjects: 0
Study 16796788 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 11931063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cramp finding positive preoperatively
Number of subjects: 133
Study 11931063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cramp finding positive postoperatively
Number of subjects: 133
Study 11931063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cramp finding compared to SLR test
Number of subjects: 133
Study 11931063 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome evaluation
Number of subjects: 133
Study 10078539 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25 mg, 3 times a day for 4 days) + glyceryl trinitrate (0.5 mg/mL infusion)
Number of subjects: 2
Study 10078539 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg) + amlodipine
Number of subjects: 2
Study 10078539 — intervention group
Group type: COMPARATOR
Intervention: Placebo + amlodipine
Number of subjects: 2
Study 7735024 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt cessation
Number of subjects: 26
Study 7735024 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper with placebo gum
Number of subjects: 26
Study 7735024 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper with active gum
Number of subjects: 26
Study 7735024 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 26
Study 1708984 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% sodium chloride in 6% dextran 70 (HSD)
Number of subjects: 422
Study 1708984 — intervention group
Group type: COMPARATOR
Intervention: Normal crystalloid solution (control)
Number of subjects: 422
Study 7238015 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day patch testing method
Number of subjects: 5
Study 7238015 — intervention group
Group type: COMPARATOR
Intervention: Aluminum chamber method
Number of subjects: 5
Study 6149491 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 24
Study 6149491 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 40 mg
Number of subjects: 24
Study 6149491 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both flurazepam and temazepam)
Number of subjects: 24
Study 30891610 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with recombinant tissue plasminogen activator (alteplase)
Number of subjects: 242
Study 30361675 — intervention group
Group type: EXPERIMENTAL
Intervention: Zein-ALA nanosphere formulation (F3)
Number of subjects: 0
Study 30361675 — intervention group
Group type: COMPARATOR
Intervention: Marketed tablets
Number of subjects: 0
Study 27806718 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based intervention using Reh@City for cognitive rehabilitation
Number of subjects: 18
Study 27806718 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 18
Study 27806718 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based intervention
Number of subjects: 18
Study 24991995 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3mg/kg etomidate
Number of subjects: 101
Study 24991995 — intervention group
Group type: EXPERIMENTAL
Intervention: 2mg/kg propofol
Number of subjects: 101
Study 24991995 — intervention group
Group type: EXPERIMENTAL
Intervention: 4mg/kg thiopental
Number of subjects: 101
Study 23201761 — intervention group
Group type: EXPERIMENTAL
Intervention: High intakes of meat (particularly high fat varieties) at age 18 months
Number of subjects: 0
Study 23201761 — intervention group
Group type: EXPERIMENTAL
Intervention: High intakes of carbohydrate at age 18 months
Number of subjects: 0
Study 23201761 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding duration less than six months
Number of subjects: 0
Study 23201761 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of solids
Number of subjects: 0
Study 20701400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 3752
Study 20701400 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesic treatment
Number of subjects: 3752
Study 18539007 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day of oral DHA
Number of subjects: 35
Study 18539007 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day of oral DHA
Number of subjects: 35
Study 18539007 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day of oral DHA
Number of subjects: 35
Study 18539007 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma DHA
Number of subjects: 35
Study 18539007 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma EPA
Number of subjects: 35
Study 18539007 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6/n-3 ratio
Number of subjects: 35
Study 15952173 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR peptide vaccination
Number of subjects: 0